Control Rate News Today

HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the...

Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2 2024 for Two Randomized...

/PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

- Luvelta demonstrated encouraging preliminary anti-tumor activity in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...

31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off

31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off... | June 11, 2023

Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle... | April 17, 2023

– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006...